Return to the Cure JM Research Page
 



Gulnara Mamyrova, M.D., Ph.D.

Research Coordinator
Division of Rheumatology
Department of Medicine
The George Washington University

Curriculum Vitae

Biography

Publications:

  1. Mamyrova G., Rider LG, Haagenson L., Wong S., Brown K. E. Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 2005; 294:2170-2171.

  2. Targoff IN, Mamyrova G., Trieu EP, Perurena O., Koneru B., O’Hanlon TP, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups.  A novel autoantibody to a 155 kd protein associated with dermatomyositis. Arthritis and Rheum. 2006; 11: 3682-3689.

  3. Mamyrova G., O’Hanlon TP, Monroe JB, Mercatante Carrick  D., Malley JD, Adams S., Reed AM, Shamim EA, James-Newton L., Miller FW, Rider LG,  for the Childhood Myositis Heterogeneity Collaborative Study Group.  Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis and Rheum. 2006; 12: 3979-87.

  4. O’Hanlon TP, Rider LG, Mamyrova G., Targoff IN, Arnett FC, Reveille JD, Carrington M., Gao X.,  Oddis CV, Morel PA, Malley JD, Malley K., Shamim EA, Chanock SJ, Foster CB, Bunch T., Reed AM, Love LA, Miller FW. HLA Polymorphisms in African Americans with idiopathic inflammatory myopathies: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis and Rheum.  2006; 11: 3670-3681.

  5. Mamyrova G., Kleiner DE, James-Newton L., Shaham B., Miller FW, Rider LG. Late-onset gastrointestinal pain in juvenile dermatomyositis (JDM) as a manifestation of ischemic ulceration from chronic endarteriopathy. Arthritis and Rheum (Arthritis Care and Research). 2007; 57: 881-884.

  6. Bingham A.*, Mamyrova G.*, Rother K., Oral E., Premkumar A., Kleiner D., Cochran E., James-Newton L., Pandey J., Carrick D., O’Hanlon TP., Ruiz-Hidalgo M., Turner M., Gordon L., Pokrovnichka A., Laborda J., Bauer S., Blackshear P., Imundo L., Targoff IN., Miller F., Rider L., for the Childhood Myositis Heterogeneity Collaborative Study Group.  Acquired lipodystrophy as a late complication of juvenile dermatomyositis. Medicine (Baltimore) 2008 (in press)  (*these authors contributed equally to this work).

  7. Mamyrova G., O’Hanlon T., Sillers L., Malley K., James-Newton L., Parks C., Cooper G., Pandey J., Miller F., Rider L., for the Childhood Myositis Heterogeneity Collaborative Study Group.  Cytokine polymorphisms as risk and severity factors for juvenile dermatomyositis in Caucasians. Manuscript submitted to Arthritis and Rheum, 2008.

Published Abstracts:

  1. Mamyrova G.O., Lindsley C. B., Adams B, Higgins G., Lovell D., Moore T., O’Neil K., Olson NY, Ramesh S., Reed A., Schikler K., Zemel L., Bowyer S., Roettcher P. Raynaud’s phenomenon in children. Arthritis and Rheum. 2002: 46: S314   

  2. Mamyrova G., Kleiner D., Bingham A., Cochran E., Imundo L., Lindsley C., Morris J., Rivas- Chacon R., Jung J., Baer A., Miller F., Oral E., Rider L. Non-alcoholic steatohepatitis (NASH) is a frequent complication of acquired lipodystrophy (LD) associated with JDM. Arthritis and Rheum. 2003: 48: S514.

  3. Mamyrova G., Targoff I., Lindsley C., Wallace C., Haftel H., Oral E., Cawkwell G., Finkel T., Gewanter H., Goldsmith D., Higgins G., Jones O., Katona I., Knee M., Lawton A., Morishima C., Passo M., Perez M., Person D., Rivas- Chacon R., Sherry D., Szer I., Zemel L., Miller F., Rider L. Distinguished clinical features of JDM associated with a myositis associated autoantibodies (MAA) directed against a 155 kd protein. Arthritis and Rheum. 2003: 48:  S514.                             

  4. Mamyrova G., O’Hanlon T., Reed A., James- Newton L., Sherry D., Wallace C., Plotz P., Lindsley C., Perez M., Henrickson M., Rivas-Chacon R., Higgins G., Katona I., Olson J., Miller F., Rider L. HLA DRB1*0301 and DQA1*0301 are independent and synergic genetic risk factors for juvenile dermatomyosits (JDM) in Caucasians. Arthritis and Rheum. 2004: 50: S 668 (oral presentation.     

  5. Mamyrova G., Haagenson L., Wong S., Perez M., Sherry D., Imundo L., Wallace C., Miller F., Rider L., Brown K. Parvovirus B19 is not associated with the onset of juvenile dermatomyositis (JDM). Arthritis and Rheum. 2004: 50: S 103.

  6. Mamyrova G., O’Hanlon T., Carrick D., Malley J., Miller F., Rider L.  DRB1*0301 and the second hypervariable region DRB1 motif, 70QKRGR74 are HLA risk factors for dermatomyositis (DM) in African American (AA) patients.  Arthritis and Rheum. 2005: 52: S 308.    

  7. Mamyrova G., Carrick D., O’Hanlon T., Malley J., Reed A., Sherry D., Wallace C., James- Newton L., Zemel L., Perez M., Lindsley C., Miller F., Rider L.  Relative importance of immunogenetic risk and protective factors for the development of juvenile dermatomyositis (JDM) in European American (EA) patients. Arthritis and Rheum. 2005: 52: S 308-309.  

  8. Vegosen L., Weinberg C., O’Hanlon T., Targoff I., Koneru B., Mamyrova G., Miller F., Rider L., and the Childhood Myositis Heterogeneity Study Group. Seasonal birth patterns in subgroups of myositis suggest a role for perinatal environmental factors in etiology. Arthritis and Rheum. 2005: 52: S 228.                                       

  9. Mamyrova G., Sillers L., O’Hanlon T., Pandey J., Malley J., Adams S., Newton-James L., Wallace C., Sherry D., Imundo L., Lindsley C., Madson K., Perez M., Miller., Rider L.Cytokine and HLA alleles modulate disease severity in juvenile dermatomyositis (JDM).Arthritis and Rheum. 2006: 54: S 692.    

  10. Mamyrova G., Sillers L., O’Hanlon T., Pandey J., Parks C., Malley J., Newton-James L., Wallace C., Sherry D., Imundo L., Lindsley C., Madson K., Perez M., Cooper G., Miller., Rider L.
    Interleukin -1 and tumor necrosis factor alpha polymorphisms are risk and protective factors for juvenile dermatomyositis (JDM). Arthritis and Rheum.
    2006: 54: S 831.    

  11. Bingham A., Mamyrova G., Cochran E., Oral E., James-Newton L., Pokrovnichka A., Imundo L., Miller FW, Rider LG, Premkumar A.
    Characteristic of regional fat loss in patients with lipodystrophy complicating dermatomyositis. Arthritis and Rheum. 2006: 54: S 169- 170.    

  12. Mamyrova G., Bingham C.A., Oral E. A., Rother K., Cochran E., Sebring N., Pandey J., James-Newton L., O’Hanlon T., Targoff I., Imundo L., Miller F., Rider L. Clinical and metabolic characteristics of acquired lipodystrophy (LD) in juvenile dermatomyositis (JDM). Arthritis and Rheum. 2007: 56: S 145-146.   

Unpublished meeting presentations:

  1. Mamyrova G., Targoff I., Lindsley C., Wallace C., Haftel H., Oral E., Cawkwell G., Finkel T., Gewanter H., Goldsmith D., Higgins G., Jones O., Katona I., Knee M., Lawton A., Morishima C., Passo M., Perez M., Person D., Rivas - Chacon R., Sherry D.,Szer I., Zemel L., Miller F., Rider L. Distinguishing clinical features of Juvenile dermatomyositis associated with a myositis –associated autoantibody (MAA) directed against a 155 kd protein. NIH Clinical Center 50-th Anniversary Research Festival (October 14-17, 2003.

  2. Mamyrova G., Haagenson L., Wong S., Perez M., Sherry D., Imundo L., Wallace C., Miller F., Rider L., Brown K. Parvovirus B19 is not associated with the onset of juveniledermatomyositis (JDM). NIH Research Festival (September 28- October 1, 2004).

  3. Mamyrova G., Kleiner DE, B Shaham, V Cartwright, L James-Newton, F Miller, L Rider.     Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic    ulceration from chronic endarteropathy and pneumatosis intestinalis.Rheumatism Society of the District of Columbia 3rd Annual Rheumatology Fellows Forum (May 14, 2005).

  4. Lindsley CB, Mamyrova G., Casey JL. Panniculitis associated with C2 deficiency and metabolic syndrome. 2005 Pediatric Academic Societies’ Meeting (May 15, 2005). 

  5.  Mamyrova G., Carrick D., O’Hanlon T., Malley J., Miller FW., Rider LG. Relative importance of immunogenetic risk and protective factors for the development of juvenile dermatomyositis (JDM) in European American patients. NIH Research Festival (October 18-21, 2005).

  6. Mamyrova G., O’Hanlon T., Monroe J., Carrick D., Adams S., Malley J., Reed A., James- Newton L., Miller F., Rider L. Immunogenetic risk and protective factors for juvenile dermatomyositis (JDM) in European Americans (EA).  Rheumatism Society of the District of Columbia 4th Mid-Atlantic Rheumatology Fellows Forum (May 6, 2006).   

  7. Mamyrova G., Sillers L., O’Hanlon T., Pandey J., Malley J., Adams S., Newton-James L., Wallace C., Sherry D., Imundo L., Lindsley C., Madson K., Perez M., Miller., Rider L. Cytokine and HLA alleles modulate disease severity in juvenile dermatomyositis (JDM) NIH Research Festival (October 17 -20, 2006).

  8. Mamyrova G., Sillers L., O’Hanlon T., Pandey J., Parks C., Malley J., Mallye K.,  Newton-James L., Cooper G., Miller F., Rider L. Tumor necrosis-1 and interleukin -1 polymorphisms as risk and protective factors for juvenile dermatomyositis (JDM).        Rheumatism Society of the District of Columbia 5th Annual Rheumatology Fellows Forum (May 12, 2007).

  9. Mamyrova G., Bingham C.A., Oral E. A., Rother K., Cochran E., Sebring N., Pandey J., James-Newton L., O’Hanlon T., Targoff I., Imundo L., Miller F., Rider L. Clinical and metabolic characteristics of acquired lipodystrophy (LD) in juvenile dermatomyositis  (JDM). NIH Research Festival 2007 September 23-28, 2007.

Last updated: January 24, 2008